Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diphenoxylate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 7/20 | 0.94 |
| ▸ | KCNA3 | P22001 | 5/20 | 0.94 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.67 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diphenoxylate SCHEMBL42940 | 0.97 | OPRM1 (1.00) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL20595320 | 0.96 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL28385054 | 0.96 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL28596518 | 0.96 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL42124 | 0.96 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL28374697 | 0.96 | OPRM1 (0.98) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL8160138 | 0.94 | OPRM1 (0.94) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Diphenoxylate SCHEMBL29019114 | 0.89 | OPRM1 (0.84) | OPRM1KCNA3OPRD1OPRK1SLC22A1 | |
| Butoxylate SCHEMBL23852174 | 0.87 | KCNA3 (0.82) | OPRM1KCNA3OPRD1OPRK1 | |
| Butoxylate SCHEMBL241324 | 0.87 | KCNA3 (0.82) | OPRM1KCNA3OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
| EP-2187892-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | Bioneris AB (SE) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009038533-A1 | METHOD AND MEANS FOR THE TREATMENT OF CACHEXIA | BIONERIS AB (SE) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | OPRM1 53/4885KCNA3 3160/4885OPRD1 103/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | OPRM1 498/4885KCNA3 2803/4885OPRD1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.